Foghorn therapeutics provides first quarter 2023 financial and corporate update

Cambridge, mass., may 08, 2023 (globe newswire) -- foghorn® therapeutics inc. (nasdaq: fhtx), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today provided a financial and corporate update in conjunction with the company's 10-q filing for the quarter ended march 31, 2023. with an initial focus in oncology, foghorn's gene traffic control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
FHTX Ratings Summary
FHTX Quant Ranking